NSCLC, STAGE III
Clinical trials for NSCLC, STAGE III explained in plain language.
Never miss a new study
Get alerted when new NSCLC, STAGE III trials appear
Sign up with your email to follow new studies for NSCLC, STAGE III, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo aims to improve lung cancer outcomes
Disease control Not yet recruitingThis phase II trial tests an immunotherapy drug called SHR-1701 combined with chemotherapy and radiation for people with unresectable stage III non-small cell lung cancer. The study will enroll 84 participants and compare giving SHR-1701 before or after standard chemoradiation. T…
Matched conditions: NSCLC, STAGE III
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New targeted pill may keep ALK lung cancer in check after standard treatment
Disease control Not yet recruitingThis study tests whether the targeted drug ensartinib can help people with ALK-mutated stage III lung cancer that cannot be removed by surgery. After completing standard chemoradiotherapy, 45 participants will receive either ensartinib or a placebo to see if the drug delays cance…
Matched conditions: NSCLC, STAGE III
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC